Molecularly Targeted Therapies in Breast Cancer: A Traditional Review

Creative Commons License

Halıcı H., Çadırcı E., Şimşek B. İ.

FABAD JOURNAL OF PHARMACEUTICAL SCIENCES, cilt.49, sa.2, ss.435-448, 2024 (Scopus)

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 49 Sayı: 2
  • Basım Tarihi: 2024
  • Doi Numarası: 10.55262/fabadeczacilik.1444169
  • Dergi Adı: FABAD JOURNAL OF PHARMACEUTICAL SCIENCES
  • Derginin Tarandığı İndeksler: Scopus, EMBASE, International Pharmaceutical Abstracts, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.435-448
  • Atatürk Üniversitesi Adresli: Evet

Özet

Globally, breast cancer stands as the most frequently diagnosed cancer among women, with its incidence continually on the rise. Conventional treatment methods for breast cancer have inherent limitations. Consequently, the development of innovative treatment approaches is imperative. Among these, targeted therapy strategies have emerged as a critical point in contemporary clinical research, significantly diversifying the treatment landscape for breast cancer in recent years. The goals of these new treatment strategies are evolving toward a future that can overcome the limitations of traditional treatment methods, protect patients from side effects, and improve patients’ survival rates and life quality. Nowadays, therapeutic agents that bind to preferred targets are used based specifically on various subtypes of breast cancer. The FDA-approved targeted therapeutic agents—such as monoclonal antibodies, gene therapies, immunotherapeutic cancer vaccines, and small molecule inhibitors, are reviewed in this article.